A simple and sensitive validated HPLC method for quantitative determination of cisplatin in human plasma

Cisplatin is an anti-tumor agent widely employed in cancer chemotherapy. A specific and selective method for the quantitative determination of cisplatin in human plasma and its applications to pharmacokinetic investigations is described. One simple ethanol-induced protein precipitation step followed by simple liquid–liquid extraction with chloroform is the only requirement as sample treatment. The resulting solution is injected into a Wakosil II (5 μm, 250 cm × 4.6 mm I.D.) analytical column. The mobile phase consisted of methanol:water:acetonitrile (40:30:30 v/v/v). The limit of quantitation was 1 μg/mL. The method showed good recovery (93.95%) and within batch recovery was 91.59–97.00%. At all levels intra- and inter-assay precision was lower than 7 and 10%, respectively. The intra- and inter-assay accuracy ranged from −2.7 to 2% and from −3.1 to 4.0%, respectively. The selectivity (discrimination between the parent drug and platinum containing species such as cisplatin metabolites), simplicity and speed of this assay for free cisplatin quantitation should facilitate pharmacokinetic investigations and therapeutic drug monitoring.

[1]  K. Devarakonda,et al.  Population pharmacokinetics of cisplatin in Asian Indian cancer patients , 2009 .

[2]  P. D. Williams The application of renal cells in culture in studying drug-induced nephrotoxicity , 1989, In Vitro Cellular & Developmental Biology.

[3]  A. El‐Yazigi,et al.  Pharmacokinetics of Platinum in Cancer Patients Treated with Carboplatin in Combination with High-Dose Methotrexate , 1989, Pharmaceutical Research.

[4]  I. Olver,et al.  Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma , 2004, Cancer Chemotherapy and Pharmacology.

[5]  L. Zufía,et al.  Simple and rapid determination of carboplatin in plasma by high-performance liquid chromatography. Error pattern and application to clinical pharmacokinetic studies. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[6]  L. Cattel,et al.  A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck. , 2001, Farmaco.

[7]  E. Walker,et al.  Evolution of chemotherapy with platinum compounds. , 1999, Annals of clinical and laboratory science.

[8]  J. Verweij,et al.  Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations , 1996, Cancer Chemotherapy and Pharmacology.

[9]  R. Kizu,et al.  A sensitive postcolumn derivatization/UV detection system for HPLC determination of antitumor divalent and quadrivalent platinum complexes. , 1995, Chemical & pharmaceutical bulletin.

[10]  I. Wilson,et al.  Drug Determination in Therapeutic and Forensic Contexts , 2012, Methodological Surveys in Biochemistry and Analysis.

[11]  L. Davis,et al.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.

[12]  R. Safirstein,et al.  Uptake and metabolism of cisplatin by rat kidney. , 1984, Kidney international.

[13]  Z. Siddik,et al.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. , 1984, Cancer research.

[14]  K. Marsh,et al.  Post-column reaction detector for platinum(II) antineoplastic agents. , 1984, Analytical chemistry.

[15]  R. W. Frei,et al.  Analysis of platinum complexes by liquid chromatogrphy with quenched phosphrescence detection , 1984 .

[16]  Z. Siddik,et al.  HPLC Analysis of Cisplatin Analogues in Biological Fluids , 1984 .

[17]  M. Weiner,et al.  Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. , 1980, The Journal of pharmacology and experimental therapeutics.

[18]  R. Gralla,et al.  Comparison of methods of evaluating nephrotoxicity of cis‐platinum , 1980, Clinical pharmacology and therapeutics.